New diabetes drug aims to protect the Body's insulin factories
NCT ID NCT07460336
Summary
This study is testing whether adding a new, long-acting drug called cofrogliptin to standard care can help preserve the body's ability to make insulin in adults with LADA, a slow-onset form of autoimmune diabetes. Over 52 weeks, 84 participants will take either standard therapy plus vitamin D, or that same therapy plus cofrogliptin. The main goal is to see if cofrogliptin helps the pancreas produce more insulin in response to a meal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Xiangya Hospital, Central South University
Changsha, Hunan, 410000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.